Found: isolation– which has knock on effects on health, increasing the risk of cardiovascular diseases, diabetes

Found: developing obesity, as well as more at risk of complications in pregnancy including gestational diabetes

Found: out that if there was early diagnosis and treatment of kidney disease you would be able to identify diabetes

Found: Questions 154 - 164 Witnesses I: Professor Dr Kevin Hall, Senior Investigator, National Institute of Diabetes

Found: used in other fields of medicine, not only in the field of obstetrics, such as with ethnicity in diabetes

Found: consistent and reliable, and have been capturing different types of populations. 11 In Chile, obesity, diabetes

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure people with diabetes can continue to access the insulin they need.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

We are aware of supply issues with some insulin products, however the vast majority are in stock. Comprehensive management guidance on alternative products has been issued to the National Health Service where needed.

The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as the other countries around the world, and it can have a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.

There is a team within the Department that deals specifically with medicine supply problems. It has well-established tools and processes to manage medicine supply issues, working closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England, and others operating in the supply chain, to help prevent shortages and expedite resupply as soon as possible, to ensure that the risks to patients are minimised.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that Tier 2 weight management services are sufficiently (a) resourced and (b) integrated with (i) primary care networks, (ii) community health hubs and (iii) other relevant providers to offer comprehensive support for people living with obesity.

Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Health Service and local government provide a range of free tier two weight management services (WMS), to help eligible people living with obesity to lose weight. These are multi-component programmes, including dietary approaches and physical activity, with behaviour change support. The length of support can vary, but guidance from the National Institute of Health and Care Excellence suggests these should last at least three months.

The NHS offers the NHS Digital Weight Management Programme, which is a tier two service aimed at adults living with obesity, who also have type 2 diabetes or hypertension, or both, as well as NHS staff living with obesity. The 12-week programme is directly commissioned and managed by NHS England nationally, and is available via direct referral from any general practice or Community Pharmacy

Local authorities are able to spend funding from the Public Health Grant on weight management services in line with local population need. They may be delivered as a standalone service or as part of an integrated service, for example with smoking cessation support. Where local authorities commission these services, they are responsible for determining the required resourcing and interaction with other services, along with weight management service providers

Local authorities are part of integrated care systems (ICSs), which are partnerships of organisations that come together to plan and deliver joined up health and care services, and to improve the lives of people who live and work in their area. ICS membership also includes the NHS, social care providers, charities, and other organisations. Being a member of the ICS will help local authorities to work more closely with partner organisations and offer integrated support for people living with obesity.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve access to weight management services in areas of socioeconomic deprivation.

Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)

Local authorities and the National Health Service provide weight management services to support their communities to achieve and maintain a healthier weight. These range from behavioural weight management programmes to specialist services for those living with obesity and associated co-morbidities.

Local authorities are able to spend funding from the Public Health Grant on behavioural weight management services in line with local population need, including in areas of socioeconomic deprivation. Integrated care boards are responsible for commissioning NHS specialist weight management services in line with local population need, as well as determining the criteria for access to these services in line with relevant guidance.

NHS England commissions the Digital Weight Management Programme nationally for people living with obesity and an existing comorbidity of either diabetes, or hypertension, or both. The 12-week programme is available via direct referral from any general practice or Community Pharmacy.

The programme provides three levels of intervention at varying intensities, and patients less likely to complete a behavioural programme of this nature, for instance those of a younger age, from ethnic minority backgrounds, from a more deprived area, or who are male, are offered a higher level of intervention and support to retain their engagement on the programme. Approximately 50% of total referrals are from the two most deprived socioeconomic quintiles.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what incentives they are offering to medical partnerships to assist type two diabetes sufferers through research into both stem-cell and non-stem-cell treatments for diabetes type one sufferers.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.

This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.

The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.

The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what incentives they are offering to commercial operators to form medical partnerships to advance stem-cell and non-stem-cell treatments for diabetes type one sufferers.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.

This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.

The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.

The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to promote international cooperation and joint research to find solutions for both type one and type two diabetes sufferers.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.

This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.

The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.

The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what partnerships and expedients they are encouraging to progress diabetes type one stem cell and non-stem-cell research.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.

This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.

The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.

The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.

Non-prepacked foods don’t require nutrition information labels. We ask the UK Government to introduce legislation requiring all food service establishments, including cafes, restaurants, takeaways, and bakeries, to display comprehensive nutrition information for non-prepacked foods.

Found: An estimated five million people in the UK have diabetes, with approximately 8% of them having type 1

Many people are able to access vital life-saving drugs for free on the NHS, such as drugs for diabetes. Anaphylaxis sufferers have to carry an Epipen throughout their life. This is undoubtedly a life-saving medication and we believe it should be free to anaphylaxis suffers.

Found: Many people are able to access vital life-saving drugs for free on the NHS, such as drugs for diabetes

Found: Optimising Islet Transplantation in Type 1 Diabetes 707 84.

Found: For example, DHSC central government partners described how funding for diabetes and heart disease is

Found: by their impairment, for example, instead of saying ‘she is diabetic’ it is better to say ‘she has diabetes

Found: by their impairment, for example, instead of saying ‘she is diabetic’ it is better to say ‘she has diabetes

Found: The percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical

Found: Peripheral Arterial Disease (PAD) 2 0 2 Stroke and Transient Ischaemic Attack (STIA) 10 5 15 Diabetes

Found: The percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical

Found: Peripheral A rterial Disease (PAD) 2 0 2 Stroke and Transient Ischaemic Attack (STIA) 6 9 15 Diabetes

Found: Diabet es Diabetes mellitus requiring insulin or oral hypoglycaemic drugs.

Found: of Diabetes.

Found: Diabetes (requiring insulin or oral hypoglycaemic drugs) This includes type I diabetes requiring insulin

Found: The percentage of patients with diabetes, on the register, with a record of a foot examination and

Found: mellitus, which specifies the type of diabetes where a diagnosis has been confirmed NICE

Found: mellitus, which specifies the type of diabetes where a diagnosis has been confirmed (NICE

Found: The percentage of patients newly diagnosed with diabetes, on the register, in the preceding 1

Found: The per centage of patients with diabetes, on the register, in whom the last blood pressure reading

Found: ending on 31st March 2019 ”; (b) in Section 2 .1 (summary of QOF indicators) — (i) in the Table headed Diabetes

Found: , which specifies the type of diabetes where a diagnosis has been confirmed NICE 2011 menu ID: NM41

Found: , which specifies the type of diabetes where a diagnosis has been confirmed NICE 2011 menu ID: NM41

Found: Case 13c.1: An elderly man with renal failure An 82 year old man with type-2 diabetes, sepsis and acute

Found: large number of subjects with a given co - morbid condition such as hypertension, heart disease, or diabetes

Found: add-on therapy to the standard of care or combination therapy is common, such as with hypertension, diabetes

Found: are also influenced by the hormonal changes around puberty (e.g., increases in insulin resistance in diabetes

Found: limited clinical data can be associated with anonymous samples (e.g., samples from subjects with diabetes

Found: prognosis or response to therapy − concomitant illness at trial initiation, such as renal disease, diabetes

Found: deficiency causes changes in the metabolism of glucose and lipids and may be associated with maturity-onset diabetes

Found: Aug-24 19-Aug-24 N/A NCFE NCFE CACHE Level 3 Certificate in Understanding the Care and Management of Diabetes

Found: Aug-24 19-Aug-24 N/A NCFE NCFE CACHE Level 3 Certificate in Understanding the Care and Management of Diabetes

Found: Diabetes. Asthma or any other breathing difficulties.

Found: ☐ ☐ Diabetes. ☐ ☐ Asthma or any other breathing difficulties.

Found: Danielle Mitch ell, University of Stirling Andy MacGregor , ScotCen Social Research Daniel O'Malley, Diabetes

Found: • Procurement of a ‘once for Scotland’ digital solution for the education and management of type 2 diabetes

Question

To ask the Scottish Government what action it is taking to address the reportedly significant waiting times for access to diabetes technology, such as insulin pumps and continuous glucose monitoring systems, for people with type 1 diabetes across Scotland, including in NHS Lothian, and what steps are being taken to meet the national targets and align with reported advancements in NHS England.

Answered by Minto, Jenni - Minister for Public Health and Women's Health

The Scottish Government’s Diabetes Improvement Plan contains a key commitment to further increase access to existing and emerging diabetes technologies.

Between 2016 and 2022, we invested £29.6 million of additional funding specifically to support the increased provision of insulin pumps and continuous glucose monitors (CGMs) and emerging technologies such as closed loop systems.

We have also invested a further £350,000 through the Accelerated National Innovation Adoption pathway to help roll out the technology faster and more efficiently across Scotland. A key focus of this project is reducing regional variation and making access to technology more equitable across Scotland.

We continue to work closely the Diabetes Managed Clinical Networks (MCNs) within each Board, including NHS Lothian, to identify and resolve any issues raised by NHS Boards regarding accessing diabetes technologies, to ensure that all available resource is targeted to support the needs of local populations.

Question

To ask the Scottish Government (a) how many and (b) what percentage of patients diagnosed with diabetes have been provided real-time glucose monitoring devices in each NHS board in each year since 1999.

Answered by Minto, Jenni - Minister for Public Health and Women's Health

This information is not held centrally.

Some information on the percentage of people using glucose monitors and other diabetes technologies can be found in the Scottish Diabetes Survey, which provides an annual summary of key issues and trends in diabetes care and treatment in Scotland. The Survey provides annual data going back to 2004 and can be found here: https://www.diabetesinscotland.org.uk/publications/#survey-docs.

The next iteration of the Survey, covering data for 2023, will be published later this year.